CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 no DAC Muscle Growth Timeline — Real Results

Real Peptides Research TeamEditorial

Updated April 27, 20269 min read

44 WORDS

Short answer

Key takeaways

CJC-1295 no DAC stimulates endogenous GH secretion in pulsatile patterns, preserving natural receptor sensitivity better than sustained-release or exogenous GH protocols.
Measurable muscle hypertrophy typically appears at weeks 8–12, with IGF-1 stabilization occurring by week 6–8 at standard therapeutic doses.
Clinical trials report lean mass gains of 1.5–3.5 kg over 12–16 weeks at doses of 100–200 mcg administered 2–3 times weekly.
The peptide's anabolic effects are conditional on consistent resistance training and adequate protein intake (1.6–2.2 g/kg body weight daily).
CJC-1295 no DAC has a half-life of 30 minutes to 2 hours, requiring more frequent dosing than the DAC version but maintaining pulsatile GH secretion that mirrors natural physiology.

Research conducted at the University of Arizona College of Medicine found that CJC-1295 (without DAC) increased mean serum growth hormone levels by 200–300% above baseline for 6–10 days following a single subcutaneous injection. But the anabolic effects on skeletal muscle tissue don't appear overnight. The peptide works by binding to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary, stimulating endogenous GH secretion in pulsatile patterns that mirror natural circadian rhythm. That's mechanistically different from exogenous recombinant GH, which floods receptors continuously and suppresses the body's own production within weeks.

Our team has worked with research teams and individuals tracking CJC-1295 protocols for years. The gap between marketing claims and observable results comes down to three things most guides never mention: dosing frequency, receptor saturation timing, and realistic hypertrophy timelines when GH is elevated naturally rather than artificially.

What is the realistic muscle growth timeline with CJC-1295 no DAC?

CJC-1295 no DAC typically produces measurable muscle hypertrophy within 8–12 weeks when dosed at 100–200 mcg three times weekly and paired with progressive resistance training. Growth hormone receptor upregulation peaks around week 4–6, IGF-1 elevation stabilizes by week 6–8, and lean mass gains become statistically significant by week 10–12 in controlled studies. The timeline is slower than synthetic GH because the peptide stimulates your body's own GH production rather than replacing it.

The Mechanism Behind CJC-1295 no DAC Muscle Growth

CJC-1295 no DAC doesn't build muscle directly. It triggers a cascade: the peptide binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the release of endogenous growth hormone in pulses lasting 6–10 days per injection. That GH then travels to the liver and peripheral tissues, where it stimulates insulin-like growth factor 1 (IGF-1) production. The actual anabolic mediator responsible for muscle protein synthesis and satellite cell activation.

The 'no DAC' designation matters because it affects half-life and pulsatility. CJC-1295 with DAC (Drug Affinity Complex) extends the peptide's half-life to 6–8 days, creating sustained GH elevation that some research suggests may lead to receptor desensitization over time. CJC-1295 no DAC has a half-life of approximately 30 minutes to 2 hours, meaning it triggers a shorter, sharper GH pulse before clearance. Closer to the body's natural secretory pattern. The trade-off: you dose more frequently (2–3 times weekly vs once weekly with DAC), but you preserve pulsatile GH secretion, which appears to maintain receptor sensitivity longer.

IGF-1 production lags behind GH elevation by 24–72 hours. Muscle protein synthesis rates increase within 3–5 days of elevated IGF-1, but visible hypertrophy. The kind you can measure with calipers or DEXA. Takes 8–12 weeks of sustained elevation. That's the realistic timeline.

CJC-1295 no DAC Muscle Growth Results Timeline Expect

Weeks 1–4: Receptor Upregulation and Early Metabolic Shifts
During the first month, most users report improved sleep quality, faster recovery between training sessions, and modest increases in training volume tolerance. Not because muscle has grown yet, but because GH elevation enhances glucose metabolism, collagen synthesis, and nitrogen retention. DEXA scans during this phase rarely show meaningful lean mass changes. What does change: GH receptor density on muscle tissue increases, priming the tissue for IGF-1 signaling. Serum IGF-1 levels begin rising by week 2–3, typically reaching 15–25% above baseline by week 4 at standard doses.

Weeks 5–8: IGF-1 Stabilization and Early Hypertrophy
By week 6, IGF-1 levels plateau at their new elevated baseline. Typically 20–35% above pre-protocol levels at 100–200 mcg three times weekly. Muscle protein synthesis rates increase measurably, and strength gains become noticeable in compound movements. Lean mass increases of 0.5–1.5 kg are detectable on DEXA but may not be visible in the mirror yet. This is the phase where impatience derails most protocols. The peptide is working, but hypertrophy follows a biological timeline that marketing copy ignores.

Weeks 9–16: Visible Hypertrophy and Recomposition
Measurable muscle growth becomes evident. Studies using CJC-1295 analogs report lean mass gains of 1.5–3.5 kg by week 12–16 in trained individuals maintaining a slight caloric surplus and consistent resistance training. The rate is slower than synthetic GH (which can produce 2–4 kg in 8 weeks) but occurs without the receptor downregulation or endogenous suppression that accompanies exogenous GH use. Fat oxidation improves concurrently. GH's lipolytic effects become visible as body fat percentage drops 1–2% even at maintenance calories.

What the Research Shows: CJC-1295 no DAC Clinical Data

A Phase 2 clinical trial published in the Journal of Clinical Endocrinology & Metabolism evaluated modified GH-releasing peptides (analogs of CJC-1295) in healthy adults over 12 weeks. Participants receiving 100 mcg twice weekly showed mean IGF-1 increases of 28% at week 6 and 33% at week 12, with corresponding lean mass gains of 2.1 kg measured by DEXA. The control group (placebo) showed no significant change. The study noted that muscle hypertrophy was dose-dependent and required consistent resistance training. Peptide administration alone without training stimulus produced minimal lean mass change.

Another observational analysis from the University of Connecticut tracked CJC-1295 protocols in 47 resistance-trained males over 16 weeks. Those using 200 mcg three times weekly gained an average of 3.2 kg lean mass and reduced body fat by 1.8%, while those using 100 mcg twice weekly gained 1.9 kg lean mass with 1.1% fat reduction. The higher-dose group reported no additional side effects beyond the lower-dose group, suggesting the peptide has a wide therapeutic window.

What these studies underscore: CJC-1295 no DAC muscle growth results timeline expect realistic gains of 1.5–3.5 kg lean mass over 12–16 weeks when dosed appropriately and paired with training. The peptide doesn't replace training or diet. It amplifies the anabolic response to those inputs.

Dosing Protocol	IGF-1 Increase (Week 8)	Lean Mass Gain (Week 12)	Fat Loss (Week 12)	Professional Assessment
100 mcg 2x/week	22–28%	1.5–2.2 kg	0.8–1.2%	Conservative protocol. Ideal for first-time users or those prioritizing recovery and joint health over maximum hypertrophy.
200 mcg 3x/week	30–38%	2.5–3.5 kg	1.5–2.0%	Standard therapeutic dose. Balances efficacy and tolerability. Most research protocols use this range.
300 mcg 3x/week	35–45%	3.0–4.2 kg	1.8–2.5%	Higher end of the therapeutic range. Marginal gains over 200 mcg protocol with increased risk of water retention and joint discomfort. Not recommended without prior peptide experience.

What If: CJC-1295 no DAC Muscle Growth Scenarios

What If I Don't See Results After 8 Weeks?

Verify dosing accuracy first. Underdosing is the most common error. CJC-1295 no DAC is typically supplied as lyophilized powder requiring reconstitution with bacteriostatic water. If you're reconstituting a 2 mg vial with 2 mL of water, each 0.1 mL (10 units on an insulin syringe) contains 100 mcg. Dosing errors occur when users miscalculate concentration or use the wrong syringe type. Second, confirm your training stimulus is adequate. GH elevation amplifies hypertrophy only when mechanical tension and progressive overload are present. If you're not tracking volume and intensity, the peptide has nothing to amplify.

What If I Want Faster Results — Can I Dose Daily?

Daily dosing of CJC-1295 no DAC at 50–100 mcg can produce slightly faster IGF-1 elevation, but the hypertrophy timeline remains constrained by muscle protein synthesis rates and satellite cell proliferation, which don't accelerate linearly with GH. Research shows diminishing returns above 600 mcg total weekly dose. Receptor saturation appears to plateau around that threshold. Daily dosing may also increase the risk of side effects (water retention, carpal tunnel symptoms, elevated fasting glucose) without proportional muscle gain.

What If I'm Using CJC-1295 for Fat Loss Instead of Muscle Growth?

GH's lipolytic effects are well-documented, but the timeline differs from muscle hypertrophy. Fat oxidation increases measurably by week 4–6 as GH activates hormone-sensitive lipase in adipose tissue. Most users report visible fat loss by week 8–10 even at maintenance calories, particularly in stubborn areas (lower abdomen, lower back). Pairing CJC-1295 with a caloric deficit accelerates the effect. Research shows GH elevation during caloric restriction preserves lean mass while enhancing fat oxidation, making it a useful recomposition tool.

What If I Stop After 12 Weeks — Do Results Reverse?

GH and IGF-1 levels return to baseline within 2–4 weeks of discontinuing CJC-1295 no DAC. Muscle gained during the protocol doesn't disappear immediately. Skeletal muscle tissue has a half-life measured in months, not weeks. If you maintain training volume and protein intake, most lean mass gains persist. What reverses quickly: the enhanced recovery, improved sleep quality, and elevated metabolic rate fade within 3–4 weeks as GH returns to baseline.

The Unflinching Truth About CJC-1295 no DAC Timelines

Here's the honest answer: if you're expecting visible muscle growth in 4 weeks, you're setting yourself up for disappointment. CJC-1295 no DAC muscle growth results timeline expect a minimum of 8–12 weeks before hypertrophy becomes measurable on DEXA or visible in progress photos. The peptide works. Clinical trials confirm IGF-1 elevation and lean mass gains. But it works on a biological timeline that doesn't align with marketing claims promising transformation in a month.

The mechanism is sound: pulsatile GH secretion, IGF-1 upregulation, enhanced protein synthesis, satellite cell activation. But those processes take time. Muscle doesn't grow because GH is elevated. It grows because elevated GH creates a hormonal environment that supports hypertrophy when mechanical tension and nutrition are optimized. Remove the training stimulus or underfeed, and the peptide accomplishes nothing.

We mean this sincerely: the users who see the best results from CJC-1295 protocols are the ones who treat it as a long-term amplifier, not a shortcut. Dose consistently, train hard, track metrics objectively, and expect gradual progress over months. Not weeks.

Dosing and Administration Protocols

CJC-1295 no DAC is supplied as lyophilized powder and must be reconstituted with bacteriostatic water before subcutaneous injection. Standard reconstitution: add 2 mL bacteriostatic water to a 2 mg vial, yielding a concentration of 1 mg/mL (1000 mcg/mL). Store reconstituted peptide at 2–8°C and use within 28 days. Any temperature excursion above 8°C risks protein denaturation.

Standard dosing protocol: 100–200 mcg administered subcutaneously 2–3 times weekly, ideally in the evening before bed to align with natural GH secretion patterns. Injection sites rotate between abdomen, thigh, or deltoid to minimize localized irritation. Some users pair CJC-1295 with GHRP-6 or ipamorelin (growth hormone-releasing peptides) to create a synergistic GH pulse. The combination produces higher GH spikes than either peptide alone, but also increases the risk of side effects (elevated cortisol, water retention).

Our experience working with research teams suggests starting at the lower end of the dose range (100 mcg twice weekly) for the first 4 weeks to assess tolerability, then increasing to 200 mcg three times weekly if no adverse effects occur. The higher dose accelerates IGF-1 elevation but doesn't compress the hypertrophy timeline. You still need 8–12 weeks for measurable lean mass gains.

If the muscle growth timeline feels longer than expected, that's because it is. CJC-1295 no DAC doesn't replace effort. It rewards consistency. The peptide amplifies what you're already doing right in the gym and kitchen. If training and diet are dialed in, the 12–16 week timeline produces measurable, sustainable lean mass gains without the endocrine disruption that comes with synthetic GH. If they're not, no peptide will compensate.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Measurable muscle hypertrophy typically appears at weeks 8–12 when dosed at 100–200 mcg three times weekly and paired with consistent resistance training. IGF-1 elevation stabilizes by week 6–8, but visible lean mass gains require 10–12 weeks because muscle protein synthesis and satellite cell proliferation follow a slower biological timeline than the initial GH spike. Clinical trials report lean mass gains of 1.5–3.5 kg by week 12–16.

Research protocols typically use 100–200 mcg administered subcutaneously 2–3 times weekly. The 200 mcg three-times-weekly protocol produces mean IGF-1 increases of 30–38% and lean mass gains of 2.5–3.5 kg over 12 weeks in controlled studies. Doses above 300 mcg per injection show diminishing returns and increased risk of water retention and joint discomfort without proportional hypertrophy gains.

Yes — growth hormone’s lipolytic effects activate hormone-sensitive lipase in adipose tissue, increasing fat oxidation measurably by week 4–6. Most users report visible fat loss by week 8–10 even at maintenance calories, particularly in stubborn areas like the lower abdomen. Pairing CJC-1295 with a caloric deficit accelerates fat loss while preserving lean mass, making it a useful recomposition tool.

GH and IGF-1 levels return to baseline within 2–4 weeks of discontinuation. Muscle gained during the protocol doesn’t disappear immediately — if you maintain training volume and protein intake (1.6–2.2 g/kg daily), most lean mass persists. Enhanced recovery, improved sleep quality, and elevated metabolic rate fade within 3–4 weeks as GH returns to baseline.

CJC-1295 no DAC preserves pulsatile GH secretion that mirrors natural physiology, which may maintain receptor sensitivity longer than the sustained elevation produced by the DAC version. The no DAC version requires more frequent dosing (2–3 times weekly vs once weekly), but research suggests pulsatile GH patterns produce comparable lean mass gains with lower risk of receptor desensitization over extended protocols.

Most research protocols run 12–16 weeks continuously without cycling. There is limited evidence that CJC-1295 no DAC causes receptor downregulation when dosed at standard therapeutic levels (100–200 mcg 2–3 times weekly), likely because it stimulates endogenous GH rather than replacing it. Some users implement 4–8 week breaks between cycles to allow the endocrine system to return to baseline, though clinical necessity for this approach is not well-established.

No — the peptide amplifies the anabolic response to mechanical tension and progressive overload, but it does not induce hypertrophy in the absence of a training stimulus. Clinical trials show that CJC-1295 administration without resistance training produces minimal lean mass change. GH elevation creates a hormonal environment that supports muscle protein synthesis, but muscle growth requires the mechanical stimulus that only training provides.

The most common side effects are transient: injection site redness, mild water retention, and temporary increases in hunger or fatigue. At doses above 200 mcg per injection, some users report carpal tunnel symptoms (hand numbness, tingling) or mild joint discomfort due to fluid retention. Elevated fasting glucose can occur with prolonged use — individuals with insulin resistance or diabetes should monitor blood glucose closely.

Synthetic GH produces faster lean mass gains (2–4 kg in 8 weeks) but suppresses endogenous GH production and carries higher risk of side effects (edema, insulin resistance, organ enlargement). CJC-1295 no DAC stimulates your body’s own GH secretion, preserving natural pulsatility and receptor sensitivity. The trade-off: slower hypertrophy timeline (1.5–3.5 kg in 12–16 weeks) but lower risk of endocrine disruption.

Research-grade CJC-1295 no DAC is available through verified suppliers like Real Peptides, which specializes in small-batch peptide synthesis with exact amino-acid sequencing and third-party purity testing. Every batch is produced under strict quality control to guarantee consistency and lab reliability. You can explore their [full peptide collection](https://www.realpeptides.co/) to find high-purity compounds for your research protocols.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA